Contact Us
Drug Search Results
More Filters [+]

Oblimersen

Alternative Names: oblimersen, g3139
Latest Update: 2023-12-20
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: BCL2 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: European Medicines Agency

Approved Indications: None

Known Adverse Events: None

Company: Genta
Company Location: BERKELEY HEIGHTS NJ 07922
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oblimersen

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Lymphoid Leukemia|Melanoma|Acute Myeloid Leukemia

Phase 2: Prostate Cancer|Kidney Cancer|Head and Neck Cancer|Adenocarcinoma|Hepatocellular Carcinoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Bladder Cancer|Carcinoma, Merkel Cell|Leukemia, Plasma Cell|Intraocular Lymphoma|Ovarian Cancer|Colorectal Cancer|Lung Cancer|Breast Cancer|Mantle-Cell Lymphoma|Follicular Lymphoma|Esophageal Cancer|Waldenstrom Macroglobulinemia|Neuroendocrine Carcinoma|Chronic Lymphoid Leukemia|Extranodal NK-T-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Male Breast Cancer|Plasmablastic Lymphoma|Liver Cancer|Lymphomatoid Granulomatosis|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Cutaneous Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Renal Cell Carcinoma|B-Cell Marginal Zone Lymphoma|Burkitt Lymphoma|Melanoma|Gastrointestinal Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Gastrointestinal Stromal Tumors|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia

Phase 1: Oncology Solid Tumor Unspecified|Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma|B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Plasmablastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Kidney Diseases|Melanoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT01200342

P2

Terminated

Melanoma

2013-09-01

0462-07-FB

P1

Terminated

Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma

2012-10-09

AGENDA

P3

Completed

Melanoma

2011-05-01

2007-003340-30

P3

Completed

Melanoma

2011-04-28

Recent News Events

Date

Type

Title

12/20/2023

PubMed

 Bcl-2 expression in cell lines breast cancer and death program.

06/13/2023

PubMed

 Metal-Organic Frameworks Facilitate Nucleic Acids for Multimode Synergistic Therapy of Breast Cancer.

02/01/2023

PubMed

 [Effect of erastin and G3139 on rat liver mitochondria in chronic alcoholic intoxication].

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions